Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : to Hold Second Quarter FY2021 Earnings Conference Calls

10/21/2021 | 08:14am EST

CAMBRIDGE, Massachusetts and OSAKA, Japan, October 21, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") will host a series of conference calls on October 28, 2021 to present financial results for the second quarter of their fiscal year 2021. Media, investors and analysts can access the live webcasts, including presentation slides, at https://www.takeda.com/investors/financial-results/during the following times:

  • 5:00 p.m. - 5:45 p.m. JST / 4:00 a.m. - 4:45 a.m. EST: Presentation and Q&A Session for Media
    (please note: media who wish to ask questions during this event should pre-register here)
  • 6:30 p.m. - 8:00 p.m. JST / 5:30 a.m. - 7:00 a.m. EST: Presentation and Q&A Session for Investors and Analysts

An archive of the webcast and copy of the presentation slides will be available at the same link following the conclusion of the event.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Media Contacts

Japanese Media

Ryoko Matsumoto
+81 (0) 3-3278-3414

U.S. and International Media

Christina Beckerman
+1 (908) 581-4133

Important Notice

For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


Takeda Pharmaceutical Co. Ltd. published this content on 21 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 October 2021 12:13:08 UTC.

ę Publicnow 2021
12/03Takeda's LIVTENCITYTM (maribavir) Now Available for Certain Individuals Ages 12 Years a..
12/03Japanese Shares Close With Gains on Japan Services Data
12/02Takeda Says Livtencity Commercially Available in the US for Patients 12 Years and Older
12/02Takeda's LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Ye..
12/02Takeda Pharmaceutical Company Limited Announces its LIVTENCITY? Now Available for Certa..
12/02Takeda Pharmaceutical Buys Back Shares for $441 Million
12/01GENERAL ANNOUNCEMENT : :Takeda Provides Update on Status of Acquisition of Own Shares
12/01TAKEDA PHARMACEUTICAL : Provides Update on Status of Acquisition of Own Shares
11/30Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduc..
11/30GENERAL ANNOUNCEMENT : :The 145th Interim Business Report (April 1, 2021 - September 30, 2..
More news
More recommendations
Sales 2022 3 407 B 30 213 M 30 213 M
Net income 2022 223 B 1 973 M 1 973 M
Net Debt 2022 3 334 B 29 566 M 29 566 M
P/E ratio 2022 21,4x
Yield 2022 5,86%
Capitalization 4 782 B 42 287 M 42 398 M
EV / Sales 2022 2,38x
EV / Sales 2023 2,25x
Nbr of Employees 47 099
Free-Float 98,2%
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 070,00 JPY
Average target price 4 322,86 JPY
Spread / Average Target 40,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010